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ABSTRACT
Objective: The aim of the present study was the enhancement in the solubility of tamoxifen citrate using solid dispersion which is considered as a 
great solution to overcome the poor water solubility behavior of tamoxifen citrate (TMX) by solvent evaporation technique using Soluplus® as a novel 
carrier then formulate it as an orodispersible tablet.
Method: A total of 24 formulas were prepared as a solid dispersion by solvent evaporation method using Soluplus® as a polymeric solubilizer in 
the ratio of 1:1, 1:3, 1:5, 1:7, and 1:10 then formulated as orodispersible tablets by incorporating three types of superdisintegrants; croscarmellose, 
crospovidone, and sodium starch glycolate (SSG) with the solid dispersion. Characterization of the formulation was done using differential scanning 
colorimetry, Fourier transforms infrared spectroscopy, X-ray diffraction, and scanning electron microscope and the best formula was selected 
according to the disintegration and dissolution tests.
Results and Discussion: Formula 22 were selected as the best formula which contains mixed types of superdisintegrants; croscarmellose and SSG 
with the fastest complete disintegration of 6.5 s and complete dissolution with <2 min.
Conclusion: Accordingly, TMX was successfully enhanced its water solubility by converting its crystalline structure into the amorphous state through 
solid dispersion with Soluplus® and formulated as an orodispersible tablet to improve its oral absorption.
Keywords: Tamoxifen citrate, Solid dispersion, Soluplus®, Orodispersible tablet, Superdisintegrants.
INTRODUCTION
One of the most challenging types of cancer is the breast cancer. 
Therefore, the incidence of it is remarkably rises making it the leading 
cause of mortality among all other types of cancer worldwide [1]. 
Tamoxifen citrate (TMX) has been used most commonly for the 
management of estrogen receptor breast cancer [2]. It is selective 
estrogen receptor modulator used in the treatment of early and 
advanced breast carcinoma in postmenopausal women [3].
On oral administration, only a limited amount of TMX is absorbed and 
reaches the blood circulation due to the low water solubility and an 
extensive first-pass metabolism [4,5]. Accordingly, there are numerous 
approaches attempted to overcome those obstacles one of them is 
by improving their water solubility through a nano sizing method or 
incorporation with coenzymes to avoid enzymatic degradation by the 
liver [5]. Solid dispersion is one of the approaches that used to improve 
the solubility of slightly soluble drugs like tamoxifen citrate since solid 
dispersion has many advantages like simplicity and low cost [6].
The solid dispersion can be defined as a dispersion of pharmacologically 
active substance through a matrix system. Usually, an inert carrier can 
be used which has the ability to disperse the drug in an aqueous medium 
either by reduce their particle size or convert it to an amorphous form 
leads to improve the solubility of the drug in water [7].
Many methods have been established to prepare a solid dispersion; 
solvent evaporation method is the most commonly used for small-scale 
preparation which include the dissolving both active pharmaceutical 
ingredient and the carrier in an organic solvent then allowed to 
evaporate to form a solid dispersion [7,8]. Furthermore, one of the most 
recent polymers that showed an enormous solubility enhancement is 
the Soluplus®, which is a polyethylene glycol polyvinyl caprolactam 
acetate grafted copolymer which is a novel thermoplastic internally 
plasticized amphiphilic polymer made for the preparation of solid 
dispersion with an excellent solubility enhancement and effective 
flowability characteristics [9].
To investigate the dissolution properties of TMX, Soluplus will be used 
to study its water solubility profile using solid dispersion and evaluate 
its characteristics by Fourier transforms infrared spectroscopy (FTIR), 
differential scanning colorimetry (DSC), particle properties study, and 
measurement of phase solubility and dissolution behavior.
MATERIALS AND METHODS
Materials
Soluplus® obtained as a gift from BASF, Germany. Crospovidone, 
croscarmellose (CC), sodium starch glycolate (SSG), mannitol, Avecil 
G102, and magnesium stearate obtained as a gift from Pioneer 
Pharmaceutical. TMX was purchased from Shijiazhuang Aopharm 
Import and Export Trading Co., Ltd.
Methods
Solid dispersion preparation
Solid dispersions were prepared using the solvent evaporation method 
with different TMX to Soluplus ratios such as 1:3, 1:5, 1:7, and 1:10.
Solvent evaporation method
An accurate amount of TMX was dissolved in a suitable amount of 
methanol, mixed thoroughly until it’s completely dissolved, after that, 
Soluplus® was added to the organic solution and mixed using a magnetic 
stirrer for about 15 min then sonicated using an ultrasonicator for 10 
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more min to assure complete dissolution. The resultant solution kept 
overnight in a desiccator for drying [10].
Characterization of TMX and solid dispersion powders
Thermodynamic solubility study
Solubility study was conducted to investigate the apparent solubility 
of TMX and the solid dispersion powders prepared by a solvent 
evaporation method. An excess amount of each powder was added to 
a 5 ml distilled water in a screw-capped sealed container maintained 
under continuous shaking (200 rpm) and protected from light at room 
temperature (about 25°C) for 48 h to achieve an equilibrium. Samples 
were centrifuged, filtered using 0.45 μ size Millipore and measured 
spectrophotometrically at 275 nm [4].
DSC
DSC was performed to examine the thermal behavior of TMX and 
the solid dispersion powder. The device used was Shimadzu, Japan 
DSC. A sample of about 5 mg of solid dispersion was packed inside a 
sealed aluminum pan and heated at a scanning rate of 10°C/min on a 
temperature range from 25°C to 300°C [11].
FTIR spectroscopy
FTIR was conducted to look into any alteration of the crystalline type of 
TMX after solid dispersion process. A sample of about 1 mg of the drug 
was grounded then mixed with potassium bromide and compressed 
through a manual press to form a thin disc and analyzed using FTIR 
spectroscopy in a range from 4000 to 400/cm [12].
Powder X-ray diffraction (XRD)
Diffraction model of TMX plain powder, Soluplus plain powder, and the 
selected solid dispersion formulation were attempted to determine the 
degree of crystallinity using (Shimadzu, Japan) X-ray diffractometer by 
utilizing Cu K α radiation with a nickel filter, a voltage of 40 kV, and a 
current of 25 mA. The samples were analyzed in a range from 5°C to 
50°C [12].
Scanning electron microscopy (SEM) analysis
The surface morphology of TMX powder and the selected solid 
dispersion formula were investigated using electron microscope 
(Shimadzu, Japan). The samples were mounted on a glass stub and 
coated with a thin layer of gold under vacuum for about 5 min in an 
argon atmosphere before an examination. Micro images with different 
magnifications were recorded to analyze surface characteristics of the 
solid dispersions [13].
Powder evaluation
Flow characteristics of TMX powder and solid dispersions blends
Flowability and compressibility are essential powder properties which 
are required for powder compression into tablets. According to USP 
pharmacopeia, an angle of repose test is used for measuring flowability 
of the powder. Furthermore, for compressibility, Hausner’s ratio and 
Carr’s index that determined using bulk density and tapped density 
measurement according to the following equation:
Carr’s index = ρp–ρb/ρp×100
Bulk density represented by ρb (g/cm3)
Tapped density represented by ρp (g/cm3)
Hausner’s ratio which is calculated according to the following equation:
Hausner’s ratio = volume before tapping/volume after tapping.
Flowability determination using the angle of repose test involves the 
use of a funnel technique in which the powder is allowed to flow throw 
a funnel of 1 cm in diameter and poured into a flat horizontal plate. The 
angle of repose then determined using the following equation:
Tan θ = h/r
In which, H is the tip height of the funnel from the surface plate and R is 
the radius of the circle that drawn around the powder pile [14].
Orodispersible tablet preparation
According to the solubility analysis, the optimized solid dispersion 
powders were selected and compressed into an orodispersible tablet 
and evaluated for further investigation. Different types of super 
disintegrants were used at different ratios as shown in Table 1; 
croscarmellose, crospovidone, and SSG. The compression of powder 
was made using a manual single punch press of 9 mm die and the 
tablets formed with a hardness of 4±0.5 kg.
Orodispersible tablet evaluation
In vitro disintegration time
The disintegration time of the prepared orodispersible tablet was 
done through USP standard specified test. One tablet was held in a six 
holes basket and immersed in 900 ml phosphate buffer 6.8 in a fixed 
motion of raising and lowering at 30 cycles/min at 37.5°C. The time 
for complete disintegration of tablets was measured and recorded [15].
In vitro dissolution time
The dissolution of TMX was carried out using USP apparatus II, the 
paddle method, in 900 ml of 6.8 phosphate buffer at 37.5°C and the 
rotation speed of the paddle was 50 rpm using (Pharmatest, Germany). 
A 5 ml samples were with drown at time intervals of 2, 4, 6, 8, 10, 15, 20, 
25, and 30 min and replaced with 5 ml of fresh dissolution medium for 
maintaining saturation solubility. The samples then filtered using 0.45 
filter syringes and analyzed spectrophotometrically at 275 nm [16,17].
Statistical analysis
The results of the experiments are given as a mean of triplicate 
samples±standard deviation and were analyzed according to the t-test 
at the level of p<0.05 [18].
RESULTS AND DISCUSSION
Thermodynamic solubility study
The intrinsic solubility of TMX and its solid dispersion formulas were 
obtained and presented in Fig. 1. The results showed that there was a 
significant increase in the solubility of TMX by solid dispersion. A gradual 
water solubility increase as the concentration of Soluplus increased. For 
1:3 ratio there is a small increase in water solubility when compared to 
1:7 and 1:10 ratios and that could be due to that at a lower concentration 
of the carrier, a higher amount of TMX was not incorporated within the 
carrier. On the other hand, with a higher concentration of the carrier, a 
larger amount of TMX dispersed within the Soluplus and improved its 
wettability. At 1:1 ratio, it presented a paradoxical effect of decreasing in 
water solubility less than the pure drug. This can be explained due to the 
glass suspension of solid dispersion and formation of a viscous layer that 
delay the hydration of TMX particle [19].
DSC
The thermal behavior of TMX and solid dispersion was obtained 
and presented a sharp peak at 147 °C for TMX as shown in Fig. 2. 
On the contrary, the widening of this peak with solid dispersion 
formula indicates the conversion of TMX crystals into an amorphous 
incorporated with soluplus.
FTIR
The results were obtained and showed a characteristic peak of TMX, 
Soluplus, and the selected solid dispersion formula. For TMX, it shows a 
sharp peak at 3080/cm for the aromatic (C-H) stretching, at 1124/cm for 
(C-O) stretching of ether, at 1704/cm for carbonyl stretching of carboxyl 
in dimmer, and at 2964/cm for the hydroxyl stretching of carboxylate. 
On the other hand soluplus, showed well-defined characteristic peaks 
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which are; 3439 cm-1 for (OH) stretching group, 2932 cm-1 for aromatic 
(CH) stretching group, 1736 cm-1 and 1638 cm-1 for carbonyl stretching 
group and 1478 cm-1 for (C-O-C) stretching group.The solid dispersion 
showed a shifting (OH) stretching group to 3460 cm-1 due to a possible 
hydrogen bonding [20, 14]. The solid dispersion showed a shifting (OH) 
stretching to 3460/cm due to possible hydrogen bonding [5,14] (Fig. 3).
Powder XRD
The results showed strong sharp peaks of TMX which are contributed 
to the higher degree of crystalline nature of its powder. The peaks 
of the solid dispersion were remarkably disappeared, due to the 
conversion of TMX from a crystalline state to an amorphous state. On 
the other hand in the physical mixture, peak intensities are clearly 
weaken when it compared to TMX alone but still present which 
indicates the presence of TMX crystals remaining in crystalline form 
(Fig. 4) [20].
SEM analysis
The results of SEM are illustrated in Fig. 5. The surface morphology of 
TMX showed a cluster of clear crystals indicates its crystallinity nature. 
On the contrary, the solid dispersion showed a smooth homogeneous 
surface characteristic as one piece and TMX losses its crystalline 
shape which indicated the conversion to an amorphous state by a solid 
dispersion [20].
Micromeritic powder evaluation
The result of the flow properties of powder is presented in Table 2. It can 
be seen that pure drug has poor powder flowability and compressibility 
features which significantly enhanced by solid dispersion through 
solvent evaporation method.
Table 1: Solid dispersion formulas composition prepared by solvent evaporation technique
Material (mg) Formula code
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
SOL (1:3) TMX 40 40 40 40 40 40
SOL (1:5) TMX 60 60 60 60 60 60
SOL (1:7) TMX
SOL (1:10) TMX
Croscarmellose 10 5 5 10 5 5
Sod. Starch 
glycolate
10 5 5 10 5 5
Crospovidone 10 5 5 10 5 5
Mg. stearate 2 2 2 2 2 2 2 2 2 2 2 2
Avicel PH 102 30 30 30 30 30 30 30 30 30 30 30 30
Citric acid 10 10 10 10 10 10 10 10 10 10 10 10
Aspartame 2 2 2 2 2 2 2 2 2 2 2 2

























F13 F14 F15 F16 F17 F18 F19 F20 F21 F22 F23 F24
SOL (1:3) TMX
SOL (1:5) TMX
SOL (1:7) TMX 80 80 80 80 80 80
SOL (1:10) TMX 110 110 110 110 110 110
Croscarmellose 10 5 5 10 5 5
Sod. Starch 
glycolate
10 5 5 10 5 5
Crospovidone 10 5 5 10 5 5
Mg. stearate 2 2 2 2 2 2 2 2 2 2 2 2
Avicel PH 102 30 30 30 30 30 30 30 30 30 30 30 30
Citric acid 10 10 10 10 10 10 10 10 10 10 10 10
Aspartame 2 2 2 2 2 2 2 2 2 2 2 2
























SOL referred to Soluplus, TMX referred to tamoxifen citrate
Fig. 1: The solubility in water of TMX and solid dispersion powder 
with Soluplus® prepared by the solvent evaporation method 
presented in mg/ml
Fig. 2: (a) Thermal behavior of tamoxifen citrate, (b) 1:3 solid 
dispersion, (c) 1:5 solid dispersion, (d) 1:7 solid dispersion, and 
(e) 1:10 solid dispersion
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Orodispersible tablet evaluation
In vitro disintegration time
Time for complete disintegration is calculated and presented in Table 3. 
The results revealed that among all formulas which contain 10% of 
superdisintegrant, CC showed the shorter disintegration time which 
is contributed to its high swelling capacity due to hydrophilic, high 
absorbent nature, and an excellent wicking mechanism contributed to 
its fibrous nature [21].
On the other hand, among all formulas which contain 5% mixed of 
two type’s superdisintegrant CC with SSG combination showed the 
fastest disintegration time which is also the shortest among the rest 
of formulas which is contributed for dual disintegration synergistic 
action with rapid water intake of SSG and many different swelling and 
disintegration mechanisms of CC [22,23].
In vitro dissolution study
Dissolution study is a crucial study for tablets that exhibit a fast release 
pattern especially orodispersible tablets in which this process attempt 
in a matter of seconds. According to the results, TMX exhibited a poor 
dissolution behavior and remains floated for most of the time of the test 
which is contributed to the higher lipophilicity nature. On the contrary, 
solid dispersion formulas showed a significant rapid, sharp release as 
Fig. 3: (a) Is the Fourier transforms infrared spectroscopy of 
Soluplus®, (b) for tamoxifen citrate, and (c) for the selected solid 
dispersion formula
Fig. 4: Powder X-ray diffraction for tamoxifen citrate pure powder, 
physical mixture, and the selected solid dispersion
Fig. 5: (a). Scanning electron microscopy (SEM) of tamoxifen 
citrate, (b) SEM of physical mixture, and (c) SEM of selected solid 
dispersion
Fig. 6: Dissolution release profile of 1:3 solid dispersion formulas 
(F1-F6) orodispersible tablets in 6.8 phosphate buffer at 37.5°C 
(Where CC is the croscarmellose, SSG is the sodium starch 
glycolate, and CP is the crospovidone)
Fig. 7: Dissolution release profile of 1:5 solid dispersion formulas 
(F8-F12) orodispersible tablets in 6.8 phosphate buffer at 
37.5°C (where CC is the croscarmellose, SSG is the sodium starch 
glycolate, and CP is the crospovidone)
Fig. 8: Dissolution release profile of 1:7 solid dispersion formulas 
(F14-F18) orodispersible tablets in 6.8 phosphate buffer at 
37.5°C (Where CC is the croscarmellose, SSG is the sodium starch 







Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 216-221
 Abduljabbar and Alhammid 
a result of higher water solubility through solvent evaporation method. 
Figs 6-9 present the dissolution behavior of formulae (F1-F24).
Factors affect dissolution profile of solid dispersion formulas
1-Effect of TMX to Soluplus ratio
As can be seen from the results, the higher the proportion of Soluplus 
to TMX the sharper and faster dissolution profile which is remarkably 
significant for formulas (F19-F24) with 1:10 TMX to Soluplus ratio. 
Among them, F22 showed the fastest and complete dissolution profile 
which is within <2 min [14].
2-Effect of type of superdisintegrant
It can be noticed from the results that formulae with a single type of 
superdisintegrant, CC presented a faster and a sharper dissolution 
behavior between all formulae which is contributed to different types 
of disintegration mechanisms; by swelling and wicking that made it 
superior to the other superdisintegrant [21].
3-Effect of mixed superdisintegrant
Formulae with mixed types of superdisintegrants showed faster and 
a sharper dissolution profiles than a single superdisintegrant. Using 
a mixture of CC and SSG provided a superior dissolution time with 
<2 min. This behavior is due to a synergistic effect between CC and 
SSG that gives combined disintegration mechanisms of wicking and 
swelling of CC and high water absorption and swelling force of SSG to 
give enormous dissolution profile.
Selection of the best formula
According to the dissolution and the disintegration results, formula 
(F22) that contain a mixed proportion of CC and SSG of 5% of each one, 
was selected as the best formula with a faster disintegration time of 
6.5 s and faster and sharper complete dissolution profile with <2 min.
Comparison between the selected formula and plain TMX
As presented in Fig. 10, formula F22 has faster and complete dissolution 
within 2 min which is highly significant than dissolution profile of 
plain TMX that showed slow with no complete dissolution. That may 
be explained by the preparation of solid dispersion using a solvent 
evaporation method can converts a crystalline nature of TMX to an 
amorphous state and enhances its water solubility, leads to an increase 
in its dissolution and disintegration rates.
CONCLUSION
TMX is an anticancer drug with a poor water solubility that was studied 
with Soluplus as a solubilizer which is, a novel polymeric carrier, using 
solid dispersion method through solvent evaporation technique then 
formulated as an orodispersible tablet dosage form. The saturation 
solubility of TMX was significantly increased through all ratios of 
Soluplus and was the highest with 1:10 ratio that increases its water 
solubility by 23 folds.
Orodispersible tablets were formulated using three different types of 
super disintegrants; CC, crospovidone, and SSG. Formula (F22) was 
selected as the best formula with a dissolution time <2 min which 
makes it succeed as an orodispersible tablet. Consequently, Soluplus is 
a promising polymeric solubilizer for poorly water-soluble drugs that 
can increase its solubility and enhances its bioavailability.
Table 2: Powder evaluation of pure drug and solid dispersion 
powder
Powder Angle of repose Carr’s index Hausner’s ratio
Pure drug 43.5±0.41 38±0.81 2.6±0.08
1:3 SD 20±0.81 18.2±0.20 1.22±0.01
1:5 SD 20.6±0.38 16.8±0.16 1.23±0.026
1:7 SD 22.7±0.32 18.03±0.28 1.25±0.024
1:10 SD 24.2±0.35 12.67±0.53 1.18±0.012
*Mean±SD, n=3
Table 3: In vitro disintegration time of the formulas prepared by 
solvent evaporation


























Fig. 9: Dissolution release profile of 1:10 solid dispersion 
formulas (F20-F24) orodispersible tablets in 6.8 phosphate 
buffer at 37.5°C (Where CC is the croscarmellose, SSG is the 
sodium starch glycolate, and CP is the crospovidone)
Fig. 10: Comparison in dissolution profile between the selected 
formula and plain tamoxifen citrate orodispersible tablets in 6.8 
phosphate buffer at 37.5°C
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